⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SPRY News
ARS Pharmaceuticals, Inc. Common Stock
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
globenewswire.com
SPRY
Form 8-K
sec.gov
SPRY
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
globenewswire.com
SPRY
Form 8-K
sec.gov
SPRY
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
globenewswire.com
SPRY
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
globenewswire.com
SPRY
Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study
businesswire.com
SPRY
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
globenewswire.com
SPRY
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
globenewswire.com
SPRY
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
businesswire.com
SPRY